Mereo BioPharma: R&D Update on Mereo’s Alvelestat Program for Alpha-1 Antitrypsin Deficiency Lung Disease
About The Event
Join us for an R&D Update with Mereo BioPharma Group plc (Mereo) featuring pulmonology experts Robert Stockley, MBBS (University Hospital Birmingham, UK) and Robert Sandhaus, MD, PhD (National Jewish Health, US). The call will feature an update on the alvelestat program for alpha-1 antitrypsin deficiency (AATD) and will include presentations from management.
A Q&A session will follow the presentations.